Dren Bio is a clinical‑stage biopharmaceutical company that develops antibody therapeutics designed to selectively deplete pathogenic cells using its proprietary Targeted Myeloid Engager and Phagocytosis Platform. Its pipeline includes two first‑in‑class clinical programs for oncology and autoimmune diseases, plus preclinical candidates across oncology, immunology, and neurology, aiming to improve efficacy while reducing off‑target toxicity.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NFounders
Product
Problem
Current treatments for cancer and serious autoimmune diseases often lack specificity, leading to off‑target effects and limited efficacy, while many pathogenic cell types remain untargeted by existing therapies.
Solution
Dren Bio is a clinical‑stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete disease‑causing cells. Leveraging its proprietary Targeted Myeloid Engager and Phagocytosis Platform, the company creates first‑in‑class agents that engage immune effector mechanisms to eliminate pathogenic cells with high precision. Its pipeline includes two clinical programs in oncology and autoimmune indications, supported by additional preclinical candidates across oncology, immunology, and neurology. By focusing on targeted cell depletion, Dren Bio aims to improve therapeutic outcomes and reduce collateral toxicity for patients with serious diseases.
Target Audience
Primary customers are pharmaceutical partners, oncology and immunology researchers, and clinicians seeking highly selective antibody therapies for cancer and serious autoimmune diseases.
Features
- Proprietary Targeted Myeloid Engager technology that directs antibodies to specific pathogenic cell populations
- Integrated Phagocytosis Platform that harnesses innate immune cells to clear targeted cells efficiently
- Two first‑in‑class clinical‑stage antibody programs evaluated in multiple cancer and autoimmune disease settings
- Broad discovery pipeline spanning oncology, immunology, and neurology for future therapeutic candidates
- Clinical‑stage development approach with emphasis on safety, selectivity, and mechanistic validation